Bayer and Dewpoint Therapeutics Ink Pact for Heart Disease Program

Bayer has made an exclusive deal with Dewpoint Therapeutics, Inc. for a heart disease program targeting dilated cardiomyopathy (DCM) patients with specific mutations. This marks the initial opportunity for collaboration between Bayer and Dewpoint Therapeutics, Inc., initiated in November 2019. It combines Dewpoint's unique biomolecular condensates platform with Bayer's expertise in small molecule drug development to create innovative therapies for cardiovascular and renal illnesses.

“One of the biggest challenges in drug discovery lies in tackling the undruggable human proteome,” said Juergen Eckhardt, M.D., Head of Business Development and Licensing at Bayer’s Pharmaceuticals Division. “The emerging paradigm of biomolecular condensates is expanding the traditional drug target space for small molecules by unveiling new targets and new approaches to previously intractable targets. We are excited to be part of this new wave of innovation together with Dewpoint Therapeutics as it is our ambition to provide transformative medicines to cardiovascular patients with the highest unmet needs.”

Dilated cardiomyopathy (DCM) is a condition affecting the heart muscle in which the ventricles become enlarged and have difficulty efficiently pumping blood. The authorized program is centered on a new approach to tackle a particular type of DCM connected to mutations that result in the creation of condensates associated with the disease. This type of DCM is a serious condition with substantial medical needs that are not being met, marked by heart failure beginning at a young age and frequent dangerous irregular heartbeats.